VRDN earnings: real EPS beat/miss history, analyst consensus Buy, P/E -5.51. Updated 2026-07-23.
Viridian Therapeutics (VRDN) Research Hub
Viridian Therapeutics (VRDN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 21.24 USD (-6.56%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.51, market cap 1.70B. This hub links to the full technical, earnings and options research available for VRDN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 21.24 USD (-6.56%) |
| 52-week range | 16.07 USD – 24.86 USD |
| Trend regime | Range |
| 14-day RSI | 36.4 (Bearish) |
| Trailing P/E | -5.51 |
| Market cap | 1.70B |
| Dividend yield | 0.00% |
Available research for VRDN
Covered Call on VRDN: how it works, illustrative setup around the real 21.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VRDN: how it works, illustrative setup around the real 21.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VRDN: how it works, illustrative setup around the real 21.24 USD price, max profit/loss, breakeven and when to use it. Educational.
VRDN technical analysis: range, last 21.24 USD, RSI 36.4, 52w range 16.07 USD–24.86 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is VRDN in?
Viridian Therapeutics (VRDN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VRDN in an uptrend or downtrend?
As of 2026-09-11, VRDN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VRDN's trailing P/E ratio?
VRDN's trailing P/E is -5.51, with a market cap of 1.70B. See the earnings research page for full valuation detail.